PARKINSON'S DISEASE and PARKINSONISM (Secondary)

All Classes (Updated 02/22/2023)

DISEASE/CONDITION	EVALUATION DATA	DISPOSITION
A. Parkinson's Disease or	Submit the following for FAA review:	
Secondary Parkinsonism Current or historical diagnosis	A current, detailed neurological evaluation that meets <u>FAA</u> Specifications for Neurologic Evaluation, generated from a clinic visit with the treating neurologist no more than 90 days before the AME exam.	Submit the information to the FAA for a possible Special Issuance.
	 It must specifically include: Unified Parkinson's UPDRS-III motor rating scale; Medication*: Comment on medications, side effects, and effectiveness of medication or treatment; Describe findings if/when an individual misses a dose of medication; Must discuss stability of the condition: Fluctuations of motor and cognitive function; dyskinesia, in response to the medication; and what is the pattern of fluctuations throughout the day; and Autonomic dysfunction such as blood pressure fluctuation or orthostasis; *Acceptable Medication(s): The only medication currently acceptable for aeromedical purposes is carbidopa + levodopa (in either long or short acting preparations). 	
	3. MRI brain (Magnetic Resonance Imaging) performed within the 12 months before the AME exam.	
	Submit the interpretive report on paper and imaging on CD in DICOM readable format (there must be a file named 'DICOMDIR' in the root directory of the CD-ROM). Please verify the CD will display the images before sending. You may wish to retain a copy of all films as a safeguard if lost in the mail.	

DISEASE/CONDITION	EVALUATION DATA	DISPOSITION
	4. A current Neuropsychological evaluation that meets FAA Specifications for Neuropsychological Evaluations for Potential Neurocognitive Impairment, generated from a clinic visit with the treating neuropsychologist no more than 90 days before the AME exam.	
B. Parkinson's Treated with Deep Brain Stimulator (DBS)	Submit the following for FAA review: 1. All Row A evaluation data 2. Operative report 3. DBS Status Summary Note: DBS and lesioning therapy may carry a risk of cognitive impairment and are reviewed on a case-by-case basis.	DEFER Submit the information to the FAA for a possible Special Issuance.